Tuberculosis is a global health issue: challenges and need for new tools by Raviglione, Mario C
ORAL PRESENTATION Open Access
Tuberculosis is a global health issue: challenges
and need for new tools
Mario C Raviglione
From Immunodiagnosis of Tuberculosis: New Questions, New Tools
Virginia, VA, USA. 21-23 September 2008
Every year, more than 9 million people are affected by
tuberculosis (TB) and 1.8 million die from it. Developing
countries are heavily affected. The highest rates per
capita are in Africa, but the largest numbers are in Asia,
with nearly 60% of the global burden. TB associated
with HIV/AIDS is a huge challenge in Africa and multi-
drug-resistant TB (MDR-TB) is frequent in the former
USSR and parts of Asia. [1]
The United Nations Millennium Development Goal
(MDG) related to TB control aims to halt and begin to
reverse the incidence of TB by 2015, and the STOP TB
Partnership targets elimination of TB as a major public
health problem worldwide by 2050. [2]
The World Health Organization (WHO) has developed
a six-point Stop TB Strategy to reach the global targets:
(i) pursue high-quality DOTS expansion and enhance-
ment; (ii) address TB/HIV, MDR-TB and other chal-
lenges; (iii) contribute to strengthening health systems;
(iv) engage all care providers; (v) empower patients with
TB; and (vi) enable and promote research. [3]
Progress has been made to date toward achieving the
global targets. Compared to performance of control pro-
grammes in the mid-1990s, up to 6 million human lives
have been saved through the implementation of DOTS,
later enhanced to the Stop TB Strategy, since 1995. The
global incidence of TB has peaked in 2004, resulting in
an earlier achievement of the MDG related to TB con-
trol. However, the decline since then has been less than
1% per year, which is insufficient to seriously target
elimination by 2050. [1]
Projections show that, even with the optimization of
the current control efforts promoted by the Stop TB
Strategy using the tools available today, efforts will
result in an incidence of TB by 2050 that is much
reduced compared to today, but about 100 times higher
than the elimination target. Thus, this target cannot be
achieved without addressing critical and urgent needs,
such as that interrupting transmission focusing on early
case detection among vulnerable groups and accelerat-
ing innovation for increased access to the best tools
available. Furthermore, new tools are needed if elimina-
tion is to be targeted assertively. Today in much of the
world, the tool most commonly used to diagnose TB,
sputum smear microscopy, is more than 100 years old,
detects only half of the TB cases and is often ineffective
in diagnosing TB in people with HIV. Rapid molecular
tests for drug resistance, although already available, are
not widely available in the field. Drugs for treatment,
which are decades old, are not compatible with some
anti-retrovirals and the treatments for MDR-TB are
lengthy, expensive, and toxic. The only vaccine, Bacillus
Calmette-Guérin (BCG), that is more than 85 years old,
protects infants from the disseminated forms of TB, but
provides unreliable protection against adult pulmonary
TB – the main source of transmission – and, as a result,
has had little impact on the global epidemic.
Therefore, diagnostics must be developed to provide
faster detection of all forms of TB (smear positive,
smear negative, and MDR-TB) and be useable at point
of care. They must provide faster results, and be more
sensitive and simpler than microscopy to make them
useable. Shorter treatment regimens and more effective
MDR-TB care regimens are priorities for drug develop-
ment. An ideal candidate would shorten the treatment
from the current six months to less than two months;
have a novel mechanism of action; not interact with
anti-retrovirals; be taken orally once daily or intermit-
tently; and be low in cost. The vaccine development
pipeline, which is focused on both pre and/or post-
infection vaccines, is still weak in research needed for
clinical trial activation.
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© 2010 Raviglione; licensee BioMed Central Ltd.The priorities to achieve success must include expand-
ing financing for TB research and development partner-
ships; attracting more researchers in academia and
industry into the TB research field; fostering more
communication between research and implementation
communities; and promoting formation of intergovern-
mental working groups to expand links across neglected
critical areas for health research. The constraints include
a recent no-growth in financing from Europe and North
America for critical research and development [4]; lim-
ited incentives for the private sector to engage more
broadly; a lack of clinical trial and manufacturing capa-
city; and limited operational research capacity and
financing.
A “TB Research Movement” has been conceived, the
goal of which is to stimulate investments, support
efforts, accelerate implementation, and expand the exist-
ing portfolio across the research continuum to ensure
development of those tools that will be conducive to
global elimination of TB by 2050. Its objectives are to
provide leadership and advocacy to mobilize increased
resources in support of a coherent and comprehensive
global TB research agenda; and to provide a forum for
funders and implementers of TB research to coordinate
plans and actions, with the result of ensuring that
research needs are addressed, opportunities prioritized,
and gaps filled.
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